Análisis opcionales del producto
Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
IQVIA Holdings Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $42.5B | |
|---|---|---|
| Revenue (ttm) | 17.3B | |
| Net income (ttm) | 1.4B | |
| EPS (ttm) | $8.25 | |
| Shares out | 164.8M | |
| P/E (trailing) | 33.8x | |
| P/E (forward) | 18.4x | |
| Volume | 1,396,426 | |
| Beta | 1.17 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $13.87B | $14.41B | $14.98B | $15.41B | $16.31B | +4.1% |
| Gross profit | $4.64B | $5.03B | $5.24B | $5.38B | $4.29B | -2.0% |
| Operating income | $1.39B | $1.80B | $1.98B | $2.20B | $2.18B | +11.9% |
| Net income | $966.0M | $1.09B | $1.36B | $1.37B | $1.36B | +8.9% |
| EPS (diluted) | $4.95 | $5.72 | $7.29 | $7.49 | $7.84 | +12.2% |
| EBITDA | $2.77B | $2.91B | $3.26B | $3.45B | $3.46B | +5.8% |
| R&D | — | — | — | — | — | — |
| SG&A | $1.96B | $2.07B | $2.05B | $1.99B | $2.00B | +0.4% |
Recent company headlines from major financial publishers.
The Base scenario reflects the modal operating path where clinical trial execution compounds at steady mid-single-digit rates, supported by multi-year trial commitments across global pharmaceutical sponsors. Technology and Analytics Solutions delivers predictable recurring revenue from proprietary syndicated prescription databases and enterprise commercial software. Operating margins expand modestly as high-margin data products gradually offset clinical site coordinator wage pressures. The house Fair value $215.19 corresponds to this trajectory, indicating -16.7% implied return from the share price $258.21 with an assigned probability of 65.0%.
Under the Bull scenario, robust biopharmaceutical venture funding accelerates Phase II and Phase III trial starts, driving double-digit net bookings in clinical research. Simultaneously, rapid adoption of artificial intelligence tools and real-world evidence platforms in commercial analytics accelerates revenue expansion and pushes operating margins toward the upper end of historical ranges. Robust cash generation enables sustained share count reduction while debt is steadily paid down. The stock reaches Potential value $256.27 under this outcome, representing -0.8% return from the share price $258.21 with a probability of 15.0%.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.7% | $224 | $227 | $230 | $233 | $237 |
| 9.2% | $216 | $218 | $221 | $224 | $227 |
| 9.7% | $208 | $210 | $215 | $215 | $218 |
| 10.2% | $202 | $204 | $206 | $208 | $210 |
| 10.7% | $196 | $198 | $199 | $201 | $203 |
Upcoming earnings date and setup when available.
La calificación que llevaba la edición de análisis publicada cada mes. Una calificación compara el precio en la fecha del análisis con el valor razonable; no es un registro de si la valoración acertó.
| Año | ene | feb | mar | abr | may | jun | jul | ago | sept | oct | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
